Genetix Biotherapeutics (BLUE) Stock Price
Genetix Biotherapeutics Price
Over the last 13 years Genetix Biotherapeutics grew revenue by 42.0% annually, reaching 83.81 M USD. For Genetix Biotherapeutics, the net margin of -287.2% is down versus -246.8% a few years ago. The consensus 12-month price target for Genetix Biotherapeutics is 8.16 USD, about 64.2% above where the stock trades today. Of 12 analysts, 6 rate the stock a buy — an overall Buy consensus.
Genetix Biotherapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genetix Biotherapeutics business model & stock analysis
Frequently asked questions about Genetix Biotherapeutics
Analysts currently set an average price target of 8.84 USD for the Genetix Biotherapeutics stock (median: 8.16 USD), implying +77.9 % versus the latest price. The consensus is based on 12 analyst ratings.
10 analysts currently rate the Genetix Biotherapeutics stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Genetix Biotherapeutics to generate revenue of 409.44 M USD and earnings per share of -1.29 USD.
Converted at the current exchange rate, the Genetix Biotherapeutics share trades at 4.44 EUR (4.97 USD).
The Genetix Biotherapeutics share (BLUE) is listed on 4 stock exchanges, including: NASDAQ (BLUE), London (0HOH.L), München (BLE.MU).
The expected revenue of Genetix Biotherapeutics is 409.44 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Genetix Biotherapeutics is -82.94 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Genetix Biotherapeutics is currently -3.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genetix Biotherapeutics stock.
The price-to-sales ratio (P/S) of Genetix Biotherapeutics is currently 0.78. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genetix Biotherapeutics stock.
The Eulerpool Quality Score for Genetix Biotherapeutics is 7/10.
The ISIN of Genetix Biotherapeutics is US09609G2093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genetix Biotherapeutics is A1W025. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genetix Biotherapeutics is BLUE. The ticker symbol is used to trade Genetix Biotherapeutics shares on the stock exchange.
Genetix Biotherapeutics stock
Genetix Biotherapeutics Peer Group
Genetix Biotherapeutics Ticker
All fundamentals and in-depth analysis of Genetix Biotherapeutics
Our stock analysis for Genetix Biotherapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetix Biotherapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.